Evogene (EVGN) Earning Somewhat Positive Press Coverage, Report Shows

News articles about Evogene (NASDAQ:EVGN) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Evogene earned a news sentiment score of 0.07 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.799935245432 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news headlines that may have effected Accern Sentiment’s scoring:

Evogene (NASDAQ:EVGN) opened at $3.80 on Tuesday. Evogene has a 12 month low of $3.60 and a 12 month high of $5.84.

WARNING: This piece was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/12/05/evogene-evgn-earning-somewhat-positive-press-coverage-report-shows.html.

Evogene Company Profile

Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.

Receive News & Ratings for Evogene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply